Trial Profile
Neoadjuvant Hormonal Therapy Combined With Chemoimmunotherapy (Taxotere, Trastuzumab and Pertuzumab) in Patients With HER2-positive and ER-Positive Breast Cancer (NeoHTTP Study)
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Fulvestrant (Primary) ; Docetaxel; Pertuzumab; Trastuzumab
- Indications Breast cancer; HER2 positive breast cancer; Male breast cancer
- Focus Therapeutic Use
- Acronyms NeoHTTP
- 25 Sep 2017 Status changed from recruiting to discontinued.
- 31 Jan 2015 New trial record